Mr Hamish Clouston
The Christie NHS Foundation Trust
Mr Clouston is a Colorectal and Peritoneal Surgeon in The Colorectal and Peritoneal Oncology Centre (CPOC) at The Christie NHS Foundation Trust. As a surgical oncologist in the CPOC he undertakes surgery for peritoneal pathology arising from tumours within the colon, rectum and appendix. This surgery includes Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. He also undertakes surgery for advanced colorectal malignancy including multivisceral rectal and colonic resections. As a core member of the anal cancer MDT he undertakes surgery for the early and recurrent anal cancers and the treatment of AIN. In his role as a core member of the neuroendocrine MDT he undertakes surgery for primary and metastatic neuroendocrine cancers.
Surgical Management of Advanced Colonic and Rectal Malignancies.
The Colorectal and Peritoneal Oncology Centre (CPOC) at The Christie NHS Foundation Trust provides a tertiary service for patients with advanced colorectal cancer in the Greater Manchester(GM) conurbation and is the GM designated single provider for advanced pelvic malignancies requiring multi-visceral exenterative resections. The seminar will focus on indications for surgery for advanced colorectal malignancy, surgical considerations and outcomes of the surgery.
EVEN MORE SEMINARS
Dr Shanmugasundaram Ramkumar University Hospital Southampton NHS Foundation Trust
Radiotherapy developments in management of recurrent rectal cancers
Dr Khurum Khan University College London Hospitals
Translational research in GI Oncology- how to make progress?
Prof Ingunn Holen Department of Oncology and Metabolism, University of Sheffield, UK
Tumour cell dormancy and breast cancer relapse
Dr Abeer Shaaban Queen Elizabeth Hospital Birmingham & University of Birmingham
Breast Pathology: Assessing tumour response to neoadjuvant chemotherapy and endocrine therapy– Pathological considerations
Dr Natalie Cook University of Manchester/Christie NHS Foundation Trust
Molecular testing and novel therapies in prostate cancer